Albertsons rated Buy on strong cash flow, digital growth, and cost savings despite risks and modest sales outlook.

Albertsons Companies is rated Buy due to its strong cash flow, expansion in digital and pharmaceutical sectors, and significant cost-saving measures amid a challenging market environment. The company trades at an attractive valuation, with intrinsic value estimated well above current levels, suggesting that much of the risk is already priced in. The FY26 guidance projects 0–1% identical sales growth and adjusted EBITDA between $3.85 and $3.925 billion, supported by increased capital expenditures to enhance digital capabilities and supply chain automation. Risks include macroeconomic headwinds from geopolitical tensions, refinancing at higher interest rates, and rising competition, but the current valuation reflects these challenges.